HeartSciences reports no FQ3 2026 revenue, cash at $3.4M; MyoVista platform advances

HeartSciences Inc.

No revenue for FQ3 2026; cash and equivalents $3.4M, shareholders' equity $2.7M as of Jan 31.
MyoVista Insights platform got major upgrade March 13; deploying across health systems.
MyoVista wavECG device submitted to FDA for 510(k) clearance in Dec 2025.
Company expects key customer wins and initial revenues during 2026.
Management to host investor call after ACC meeting to demo platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.